The U.S. National Cancer Institute (NCI) Cancer Moonshot Biobank launched in September 2020, with the aim of accelerating cancer research by creating a resource of well-annotated, longitudinal cancer biospecimens from patients receiving standard-of-care therapy. The Biobank will serve research needs of funded grantees working to better understand the mechanisms and systems biology of drug resistance…

The immune checkpoint inhibitors (ICIs) monotherapy has resulted in significant improvements in PFS and OS in advanced NSCLC when compared with chemotherapy alone, and it has become the standard of care as first-line treatment for patients with EGFR- and ALK-negative advanced NSCLC1 ,2 . However, patients with high PD-L1 expression are preferred population and almost…

In February 2021, the American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) published a joint guideline update to the 2017 ASCO guidelines regarding systemic therapy for stage IV NSCLC. This update focused on therapy for patients with stage IV NSCLC with driver alterations, and it discussed treatment options for ROS1 fusions…

Because nearly one-half of patients with advanced cancer are eligible for immune checkpoint inhibitor (ICI)–based treatment, these therapies are now in widespread clinical use.1 ICIs—whether as monotherapy, in checkpoint inhibitor combinations, with chemotherapy, or after concurrent chemoradiation—are now incorporated into treatment regimens for most types of lung cancer, resulting in prolonged responses for a small…